Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia
Completed · Not applicable · Has a placebo group
Conditions studied: Insomnia, Schizophrenia, Schizoaffective Disorder, Sleep Disorders
In brief
The major goal of this project is to investigate established insomnia treatments in a schizophrenia population to see if the improved sleep leads to overall better quality of life. In addition, we hypothesize that the insomnia treatment may also lead to observed improvements in other symptoms associated with schizophrenia such as cognitive impairments, obesity, and negative symptoms.
Key facts
- Study ID
- NCT00645944
- Run by
- Yale University
- People needed
- 39
- Starts
- 2008-04-01
- Expected to finish
- 2011-04-01
- Last updated by the study team
- 2015-07-16
Who can join
Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Be between the ages of 18 to 64
- Meet DSM-IV criteria for schizophrenia or schizoaffective disorder
- Sleep difficulties at least 2x per week in the preceding month
- Be on a stable dose of antipsychotic medication
- Symptomatically stable in the last 2 months
- English speaking.
You may not qualify if…
- Meet criteria for current alcohol or other substance dependence
- A history of dementia, mental retardation or other neurological disorder
- Not capable of giving informed consent for participation in this study.
- Ongoing pregnancy
- Known sensitivity to zopiclone.
- Insomnia associated with medical disorders likely to impair sleep.
- Use of any medication that affects sleep/wake function (other than antipsychotic medication), within the past 2 weeks or within a time period that is less than 7 half-lives since last use of the medication.
- Lack of sleep benefit from previous adequate eszopiclone treatment
- History of clinically significant hepatic impairment.
- Subject is taking a potent cytochrome p450 3A4 inhibitor medication (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) and is unwilling or it is clinically contraindicated to stop the medication.
Where it is running
- Connecticut Mental Health Center — New Haven, Connecticut, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.